The proposal should be three pages long, for around 50,000-500,000 for a period of 1-3 years. Companies and academic labs are both invited. As someone in the field said - its time to move the needle and make some new progress.

1Establishing a method to generate delivery of secondary energy sources in vivo that reaches mitochondria and overcome barriers such as skin. 2Demonstrating that the combined work of 1 2 is able to synthesize a threshold of 10% synthetic ATP generation

Design of synthetically upgraded mitochondria with the ability to absorb an alternative power source to synthesize ATP independently of oxygen in a mammalian tissue (like the eye) . For example, inner membrane-integrated light-activated proton pumps

ANNOUNCEMENT FOR POTENTIAL FUNDING There is going to be (soon) a call for funding where you are encouraged to submit a proposal on upgrading our mitochondria (Mito 2.0) to be able to utilize a secondary energy source (e.g. photosynthetic mitochondria). These are potential points

This is WILD! MIT just solved one of the hardest unsolved problems in robotics (Save this). For decades, the fundamental problem with soft robots and wearable exoskeletons has not been compute or AI, it has been actuation. The moment you try to give a soft robot meaningful strength, you run into the same wall every engineer has hit since the field began, fluid-driven systems require external pumps, hydraulic reservoirs, and heavy infrastructure that makes the entire thing impractical to wear or embed into fabric. MIT's new Electrofluidic Fiber Muscles solve that problem by eliminating external infrastructure entirely. The key insight is electrohydrodynamic pumping using electric fields to generate pressure directly from electricity, with no moving parts, no motors, and no external fluid reservoir. The fibers are less than 2 millimeters thick, can be woven into fabric like ordinary textile, and operate in complete silence because nothing physically moves inside them, it is just ions propelling fluid through a closed circuit. The performance numbers published in Science Robotics are not conceptual, they are empirical results from actual hardware. These fibers achieve a power density of 50 watts per kilogram, matching skeletal muscle, with a contraction strain of 20% and a response time of 0.3 seconds. A single bundled configuration lifted 4 kilograms, 200 times its own weight while a separate configuration drove a robotic arm through a 40-degree bend compliant enough to safely complete a human handshake. Another configuration launched objects in under 100 milliseconds, which is faster than a human flinch reflex. The design mirrors biological muscle architecture in a way that prior artificial muscle approaches never achieved. The fibers are organized into antagonistic pairs, one contracts while the other extends, exactly like biceps and triceps and because the system runs in a closed loop, the relaxing fiber serves as the fluid reservoir for the contracting one, which is what allows the whole system to operate untethered with no external tank. The applications are not hypothetical but rather are the exact use cases the industry has been waiting years for the hardware to catch up to. Exoskeletons for physical labor, prosthetic limbs that move with the natural compliance of biological tissue, assistive garments for patients with motor disorders, and soft robots capable of safe physical contact with humans are all immediately unlocked by a muscle technology that is silent, lightweight, and weavable into clothing. The deeper significance is what this technology does when it meets the AI robotics wave that is already underway. Every major humanoid robot program, Figure, 1X, Boston Dynamics, Tesla Optimus is currently bottlenecked by the same hardware limitations these fibers address, actuators that are too rigid, too loud, too heavy, or too dependent on infrastructure to operate naturally alongside humans. Electrofluidic fiber muscles do not just solve a materials science problem but rather they remove one of the last physical barriers between robots that live in labs and robots that live in the world.

What happens to the heart when people stop GLP-1 drugs? The short answer: nothing good. New from our team: a study of 330,000 people in @BMJMedicine 🧵